InspireMD director buys 75,626 shares in market
InspireMD, Inc. director Paul Stuka reported open-market purchases of the company’s common stock.
Rhea-AI Filing Summary
InspireMD, Inc. director Paul Stuka reported open-market purchases of the company’s common stock. On May 8, 2026, he bought 65,626 shares at a weighted average price of $1.16 per share, followed by another 10,000 shares on May 11, 2026 at a weighted average price of $1.19 per share.
After these transactions, Stuka directly beneficially owned 632,871 shares of InspireMD common stock. Footnotes state that, immediately before these trades, he directly owned 557,245 shares and indirectly, through Osiris Investment Partners, L.P., beneficially owned 423,704 shares. The Osiris-held shares are reported for informational purposes, with Stuka disclaiming beneficial ownership except to the extent of his pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 10,000 | $1.19 | $12K |
| Purchase | Common Stock | 65,626 | $1.16 | $76K |
| holding | Common Stock | -- | -- | -- |
Footnotes (5)
- F1. The price reported is a weighted average price. The reported securities were purchased in multiple transactions at prices ranging from $1.15 to $1.16. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- F2. The Form 4 filed on August 1, 2025 (the "Original Filing") (and subsequent Form 4s reflecting this information) inadvertently reported that 20,661 shares of common stock purchased on July 30, 2025 were indirectly held by the Reporting Person through Osiris Investment Partners, L.P. ("Osiris"). However, such shares were held directly by the Reporting Person. After adjusting for the foregoing and further technical adjustments, the Reporting Person (i) directly beneficially owned 557,245 shares of Common Stock and (ii) indirectly, through Osiris, beneficially owned 423,704 shares of Common Stock, in each case immediately prior to the transaction reported herein.
- F3. This Form 4 reflects the Reporting Person's correct beneficial ownership following the transaction reported herein. No change in the Reporting Person's pecuniary interest resulted from these corrections.
- F4. The price reported is a weighted average price. The reported securities were purchased in multiple transactions at prices ranging from $1.17 to $1.20. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- F5. These securities are held by Osiris. The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes. No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
Key Figures
Key Terms
open-market purchase financial
weighted average price financial
beneficial ownership financial
pecuniary interest financial
indirectly beneficially owned financial
FAQ
What insider transactions did InspireMD (NSPR) disclose in this Form 4?
Were the InspireMD (NSPR) insider transactions open-market purchases?
What corrections to prior InspireMD (NSPR) ownership reporting does this Form 4 note?
AI-generated analysis. How Rhea-AI works. Not financial advice.